

15 February 2016

## Company Update

Antisense Therapeutics (“ANP” or the “Company”) wishes to advise on the status of key elements of its projects.

### **ATL1103/COR-004 for acromegaly/endocrinology applications– Licensed to Strongbridge Biopharma plc.**

ANP’s partner Strongbridge advised on 19<sup>th</sup> November 2015 in a corporate update that they were engaging with regulatory agencies to determine future development plans for COR-004. They also specified that they were pursuing orphan drug designation for COR-004. ANP are awaiting advice back from Strongbridge on their progress and their development plans for COR-004.

### **ATL1102 for Multiple Sclerosis – Early Access Program (EAP) with myTomorrows (for the potential treatment of MS patients who have no other treatment options) and partnering interactions**

ANP is in the final stages of drug manufacture and formulation for potential use in the EAP. The drug compound has been manufactured with the formulation of this material into injectable product scheduled for next month in line with previous guidance. Once the manufacture and formulation of this ATL1102 material is completed, myTomorrows will then be able to seek EAP approvals in select European countries as well as financially acceptable reimbursement for drug supply.

Separate to the EAP, the Company continues to have ongoing interactions with a number of potential pharmaceutical and development partners that has included the sharing of supportive data under confidentiality agreement on the drug’s potential as a treatment in Secondary Progressive MS.

Additionally, ANP previously reported that the US Food and Drug Administration (FDA) had responded affirmatively to the Company’s plan to submit a US Investigational New Drug (IND) application for initiation of longer term Phase IIb human trials of ATL1102. The Company intends to submit an IND application in the coming months. An IND approval for a Phase IIb trial of ATL1102 would further support the drug’s commercialisation.

The Company will continue to report on material developments in commercialization plans for ATL1102 in MS.

### **Contact Information:**

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director: Mark Diamond +61 (0)3 9827 8999

### **About Antisense Therapeutics Limited**

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Ionis Pharmaceuticals Inc. (formerly Isis Pharmaceuticals Inc.), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHR production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.